19 results about "Antigen response" patented technology

The present disclosure provides methods for identifying T-cell receptors (TCRs) from sequencing data, and TCR sequences identified using the methods. The methods can comprise identifying a TCR alpha chain, a TCR beta chain, a TCR gamma chain, or a TCR delta chain from the sequencing data, and then identifying the corresponding paired chain. The "de novo" method can comprise the identification of statistically associated TCR chain sequences by assessing patients' antigenic status and / or HLA alleles. In the "bait" method, a TCR chain sequence of a TCR known to have some degree of antigen reactivity can be used to search for related sequences in the large database. Resulting sequences may or may not exhibit statistical enrichments that can be detected using the "de novo" approach. Various pairing methods are provided. Identified paired TCR chains can be used for preparing various therapies including cell-based therapies.

Provided herein are CasX:gNA systems, and compositions and methods relating thereto, the systems comprising CasX proteins, guide nucleic acids (gNAs), and optionally donor template nucleic acids useful for the modification cell genes encoding proteins involved in antigen processing, antigen presentation, antigen recognition, and / or antigen response, as well as methods of producing and using populations of cells comprising these modified genes. In some embodiments, the modified cells further express chimeric antigen receptors (CAR) or engineered T cell receptors (TCR). Such systems are useful for preparing cells for immunotherapy.

An antibody for use in an immunoassay method, the antibody comprising an Fc region, wherein at least part of a glycan comprised in the Fc region has been removed.

The present disclosure relates generally to antibodies reactive with tumor-specific neoantigens, as well as neoantigen-binding fragments thereof. The present disclosure also relates to nucleic acids, expression cassettes, and expression vectors encoding the antibodies and neoantigen-binding fragments. The antibodies and neoantigen binding-fragments are useful for diagnosis and treatment of cancer.

To provide an antigen responsiveness enhancer. [Solution] From Euglena, paramylon, paramylon processed product, and β-1,3-glucan An antigen response enhancer containing at least one selected from the group.

A system and method for diagnosing traumatic brain injury (TBI) includes a proteome biochip including a set of brain protein fractions including primary serum autoantibodies reactive with brain protein autoantigens released by the TBI printed into micro-wells of a glass slide. The biochip hybridized with non-TBI and TBI-injured serum samples from which an autoantibody response profile is generated. The system additionally including labeled IgG or IgM secondary antibodies for addition to the micro-wells for binding with one of the primary serum autoantibodies, a side illumination laser to read the micro-wells in which the labeled IgG or IgM secondary antibodies are bound with one of the primary serum autoantibodies, and a readout detection system for the set of brain protein fractions to screen for autoantigens present in the micro-wells that contain the labeled IgG or IgM secondary antibodies bound with one of the primary serum autoantibodies to generate a heat map.

The invention provides a nano vaccine vector based on cholesteroid-free capsule protein and application of the nano vaccine vector, and belongs to the technical field of nano particle vaccines. The nano vaccine carrier is formed by sequentially connecting cholesteroid-free capsule protein, extension peptide, linker and molecular glue from an N end to a C end. The invention also provides a nano vaccine based on the cholesteric plasma-free capsule protein. The antigen is obtained by reacting the carrier with an antigen connected with SpyTag, SpyTag002 or SpyTag003. The invention also provides a mycoplasma hyopneumoniae nano vaccine and a new crown nano vaccine. The antigen is obtained by reacting the carrier with an antigen connected with SpyTag003. The nano vaccine vector disclosed by the invention can be used for intramuscular injection vaccines and mucosal vaccines for human and livestock, can remarkably improve the immune effect and enhance the immune response while displaying antigens, has a remarkable self-adjuvant effect, and provides a safe and efficient potential choice for the development of subunit vaccines.

The application discloses a chicken interleukin 2 antibody and application thereof, the antibody comprises a light chain and a heavy chain variable region, the amino acid sequences of three complementarity determining regions in the light chain variable region are respectively shown as SEQ ID NO. 1-3, the amino acid sequences of three complementarity determining regions in the heavy chain variable region are respectively shown as SEQ ID NO. 5-7, or the amino acid sequences of three complementarity determining regions in the light chain variable region are respectively shown as SEQ ID NO. 17-19, and the amino acid sequences of three complementarity determining regions in the heavy chain variable region are respectively shown as SEQ ID NO. 21-23. The antibody provided by the application has the advantages of high effective value, good specificity, high affinity and reaction with natural ChIL-2 antigen. The ChIL-2 double antibody sandwich enzyme-linked immunosorbent assay (ELISA) established based on the two antibodies has the advantages of high specificity, high sensitivity, simple operation and good repeatability, and can be used for determination of the ChIL-2 content in cell culture supernatant, chicken serum and other samples.

The invention discloses denatured IgG for determining rheumatoid factors, a preparation method of the denatured IgG, a detection reagent and a kit, and relates to the technical field of rheumatoid factor detection. The preparation method of the denatured IgG for measuring the rheumatoid factors comprises the following steps: carrying out thermal denaturation treatment on IgG to obtain first denatured IgG; mixing the first denatured IgG with basic amino acid to obtain second denatured IgG; mixing the second denatured IgG with a denaturant to obtain third denatured IgG; and mixing the third denatured IgG with a cross-linking agent, and carrying out a cross-linking reaction to obtain the denatured IgG for measuring rheumatoid factors. According to the present invention, the antigen epitope is completely exposed, and the antigen reaction activity is enhanced, such that the RF detection sensitivity is improved, the linear range is widened, and the HOOK ability is improved.

The present disclosure relates generally to antibodies reactive with tumor-specific neoantigens, as well as neoantigen-binding fragments thereof. The present disclosure also relates to nucleic acids, expression cassettes, and expression vectors encoding the antibodies and neoantigen-binding fragments. The antibodies and neoantigen binding-fragments are useful for diagnosis and treatment of cancer.

The present invention relates to compositions for detecting a lung cancer disease, comprising peptide affinity ligands for detecting different combinations of proteins of different groups of biomarkers which include CYFRA 21-1, Prolactin, Squamous Cell Carcinoma Antigen (SCC), Her2 / Neu, Cancer antigen 125 (CA125), carcinoembryonic antigen (CEA), C- reactive protein (CRP), Neuron Specific Enolase (NSE), C4 complement (C4), Interleukin 6 (IL-6), and Metallopeptidase Inhibitor 1 (TIMP-1). The invention further relates to methods of detecting or subtyping lung diseases, as well as to computer-implemented methods based on machine learning methods using expression data of the biomarkers.

This invention relates to a genetically engineered bacterial outer membrane vesicle and its preparation method. By using in-cell peptides to attach exogenous proteins to the surface of OMVs via peptide bonds, a variety of desired antigens can be conveniently delivered. The reaction conditions are mild, less affected by antigen size, and unlike the SpyCatcher / SpyTag system, the in-cell peptides do not remain in the mature protein after attaching the exogenous protein to the OMV surface. This invention can serve as a universal tool for simultaneously or separately displaying different antigens on the surface of OMVs.

The present disclosure provides methods for identifying T-cell receptors (TCRs) from sequencing data. The methods can comprise identifying a TCR alpha chain, a TCR beta chain, a TCR gamma chain, or a TCR delta chain from the sequencing data, and then identifying the corresponding paired chain. The "de novo" method can comprise the identification of statistically associated TCR chain sequences by assessing patients' antigenic status and / or HLA alleles. In the "bait" method, a TCR chain sequence of a TCR known to have some degree of antigen reactivity can be used to search for related sequences in the large database. Resulting sequences may or may not exhibit statistical enrichments that can be detected using the "de novo" approach. Various pairing methods are provided. Identified paired TCR chains can be used for cell-based therapies.

This invention relates to the field of tumor vaccines, specifically to an anti-tumor vaccine, its preparation method, and its application. The invention prepares an anti-tumor vaccine, BCG-CW@LNT, by mixing cell walls extracted from BCG vaccine as an immune adjuvant with LNT cells obtained from tumor cells through rapid freeze-thaw cycles in liquid nitrogen. This vaccine utilizes these "therapeutic dead cells" to induce a broad antigen response throughout the entire cell, mimicking the natural presentation of antigens in the tumor microenvironment, thereby enhancing anti-cancer immunity. In bladder cancer and lung cancer models, BCG-CW@LNT demonstrated good anti-tumor therapeutic effects. Furthermore, due to the presence of memory T cells, it exhibits a long-term memory effect, providing long-term anti-tumor and preventative effects, effectively preventing tumor recurrence and offering a novel option for tumor treatment.

Various embodiments of the invention provide compositions of tumor infiltrating lymphocytes (TILs) enriched in tumor reactive cells, methods for manufacturing TILs enriched in tumor reactive cells and methods and uses of the provided enriched tumor reactive TILs for treating cancer in a human or other subject. Among the provided embodiments of TIL compositions may include those that exhibit substantial tumor reactivity activity, including degranulation and the ability to express one or more of IFN-gamma and TNF-alpha, in response to antigen presenting cells presenting neo antigenic peptides.

The present disclosure provides methods for identifying T-cell receptors (TCRs) from sequencing data. The methods can comprise identifying a TCR alpha chain, a TCR beta chain, a TCR gamma chain, or a TCR delta chain from the sequencing data, and then identifying the corresponding paired chain. The "de novo" method can comprise the identification of statistically associated TCR chain sequences by assessing patients' antigenic status and / or HLA alleles. In the "bait" method, a TCR chain sequence of a TCR known to have some degree of antigen reactivity can be used to search for related sequences in the large database. Resulting sequences may or may not exhibit statistical enrichments that can be detected using the "de novo" approach. Various pairing methods are provided. Identified paired TCR chains can be used for cell-based therapies.

Various aspects of the present invention provide compositions of tumor-infiltrating lymphocytes (TILs) enriched for tumor-reactive cells, methods for producing TILs enriched for tumor-reactive cells, and methods and uses of the provided enriched tumor-reactive TILs for treating cancer in humans or other subjects. Among the provided aspects of the TIL compositions can be TIL compositions that exhibit substantial tumor-reactive activity, including degranulation and the ability to express one or more of IFN-γ and TNF-α in response to antigen-presenting cells that present neo-antigenic peptides. TIFF2025537148000002.tif51170

Disclosed is a method of providing antigen-reactive lymphocytes comprising: (a) obtaining lymphocytes of an individual wherein the individual carries at least one antigen; (b) establishing a primary culture of lymphocytes; (c) introducing a transient reporter system into the lymphocytes of the primary culture, wherein the reporter system generates a signal upon activating the nuclear translocation of the T cell nuclear factor (NFAT); (d) attacking the lymphocytes with at least one antigen; and (e) screening at least one antigen-reactive lymphocyte from the lymphocytes by detecting the signal. Also disclosed are pharmaceutical compositions comprising amplified antigen-reactive lymphocytes obtained by the method and kits for performing the method.

The invention discloses a Dermatophagoides farinae allergen specificity IgE quantitative detection kit and a preparation method thereof. The Dermatophagoides farinae allergen specificity IgE quantitative detection kit comprises a coating antigen, an anti-human IgE antibody marked by a luminescent substance, and a calibrator, the coating antigen is a biotinylation-dermatophagoides farinae allergen extract and a biotinylation-dermatophagoides farinae allergen component Der f2, wherein the biotinylation-dermatophagoides farinae allergen extract is coated by streptavidin magnetic beads. According to the kit, the mixed antigen is prepared by adopting a special coating process, so that the detection sensitivity is effectively improved, the kit is particularly suitable for detection of low-concentration samples, the specificity and efficiency of antigen reaction are improved, and the accuracy of a detection result is improved.